Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 2Unknown 1Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 3Observational 2

Sponsor

Cancer Type

Thoracic 12Other hematologic neoplasm 9Gastrointestinal 7Myeloid 5Gynecologic 5Genitourinary 5Tumor-Agnostic 2CNS 2Head & Neck 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Philadelphia Chromosome 1Neoplasm, Residual 1Leukemia 1

Interventions

Cyclophosphamide 261fludarabine phosphate 233Azacitidine 182fludarabine 181Busulfan 176Cytarabine 155Imatinib Mesylate 152Mycophenolic Acid 148Tacrolimus 146Whole-Body Irradiation 142Peripheral Blood Stem Cell Transplantation 140Cyclosporine 110Antilymphocyte Serum 108Melphalan 107Methotrexate 105Filgrastim 101Decitabine 98nilotinib 94venetoclax 79ruxolitinib 79Dasatinib 68Granulocyte Colony-Stimulating Factor 66Stem Cell Transplantation 63Thiotepa 60Radiotherapy 60thymoglobulin 52Specimen Handling 49Etoposide 49Clofarabine 46Cord Blood Stem Cell Transplantation 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Tyrosine Kinase Inhibitors × Myeloid × Clear all
NCT07413263 2026-02-18

Impact of Tyrosine Kinase Inhibitors on Glucose Level and Lipid Metabolism in Chronic Myeloid Leukemia Patients

Assiut University

Not yet recruiting
75 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05476562 2022-11-08

Study Conducted Among Patients With CML

Novartis

Completed
3,234 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01460498 2020-03-05

Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)

M.D. Anderson Cancer Center

Phase 1 Completed
3 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual

NCT02730195 2019-01-09

Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia

Emory University

Phase 2 Terminated
9 enrolled 8 charts
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02687425 2016-02-22

SESPI

Tongji Hospital

Phase 2 Unknown
20 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡